RxDoctor Payments DataLook up a doctor →

Steven Ing, MD

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1821005034

Payments from drug & device makers

$1,875,380in general payments, 2019–2025

Across 486 payments — averaging $3858.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1M
  • Takeda Pharmaceuticals U.S.A., Inc.$269K
  • Shire North American Group Inc$171K
  • Ultragenyx Pharmaceutical Inc.$168K
  • Chugai Pharmaceutical Co., Ltd.$115K
  • Radius Health, Inc.$75K
  • plus $50K from 4 others
$1,081in research payments, 2019–2025

Across 2 payments — averaging $540.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Radius Health, Inc.$1K

What the payments were for

  • Consulting fees$24,50565%
  • Speaking & faculty fees$4,17411%
  • Travel & lodging$4,31612%
  • Food & beverage$1,7565%
  • Education$2,6957%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,875,380 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$40,956
Medicare patients
358
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StrensiqAsfotase Alfa52$4,801,650
ForteoTeriparatide236$886,018
CrysvitaBurosumab-Twza13$524,930
Teriparatide138$320,529
TymlosAbaloparatide21$44,702
Cinacalcet Hcl31$11,807
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic91$5,218
Risedronate Sodium44$4,555
Calcitriol174$3,513
Potassium Citrate ErPotassium Citrate28$2,765
Nano 2nd Gen Pen NeedlePen Needle, Diabetic36$1,976
Alendronate Sodium321$1,835
SynthroidLevothyroxine Sodium24$1,453
Levothyroxine Sodium53$727
Chlorthalidone44$644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaStrensiq$1,028,880$4,801,65052 claims
Kyowa Kirin, Inc.Crysvita$6,763$524,93013 claims
Radius Health, Inc.Tymlos$74,702$44,70221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →